LIVE MARKETS-Before the bell: Europe meets midterms with a shrug

By Reuters News

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com.

BEFORE THE BELL: EUROPE MEETS MIDTERMS WITH A SHRUG

European shares were set to open slightly lower on Wednesday, as investors processed Democrats seizing control of both the US Senate and House on Tuesday.

Europe's tech sector, small in comparison with those in the US and Asia, will be one focus as trading gets going, given the possibility a Democratic-led Congress could exert greater scrutiny over AI companies, in part due to growing public opposition to data centres.

But a rotation out of chips could see gains for defensive sectors. European healthcare stocks could also see some activity.

US futures dropped sharply as the scale of the Democratic wave became clear, but those moves faded. S&P 500 futures were last down 0.1% and even Nasdaq 100 futures were down just 0.25%. Russel 2000 futures were 0.3% higher, suggestion a rotation rather than indiscriminate selling.

There's another batch of earnings to digest too.

Top of mind will be Novo Nordisk, NOVOb.CO whose Wegovy pill beat third-quarter sales forecasts on Wednesday, a test of whether the Danish drugmaker's new oral weight-loss drug can help it regain lost ground to rival Eli Lilly.

Traders are calling its shares up around 2% at the open.

They are calling BMW shares lower after its pre-tax earnings fell in line with expectations in the third quarter with hefty restructuring charges looming towards the end of the year. BMWG.DE

On the US market, shares in Elon Musk's Tesla TSLA.O and SpaceX SPCX.O were among the worst performers on Tradegate, both down around 5%, compared with losses of between 0.4% and 1.2% for other tech stocks, such as Microsoft MSFT.O, Alphabet GOOGL.O and Nvidia NVDA.O.

(Alun John)

EARLIER LIVE MARKETS POSTS:

MORNING BID: MARKETS FRET BLUE WAVE WILL DROWN DATA CENTRES CLICK HERE

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.